[1] |
Agarwal AK, Simha V, Oral EA, et al. Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy[J]. J Clin Endocrinol Metab, 2003, 88(10):4840-4847.
doi: 10.1210/jc.2003-030855
URL
|
[2] |
Akinci B, Onay H, Demir T, et al. Natural History of Congenital Generalized Lipodystrophy: A Nationwide Study From Turkey[J]. J Clin Endocrinol Metab, 2016, 101(7):2759-2767.
doi: 10.1210/jc.2016-1005
pmid: 27144933
|
[3] |
Magré J, Delépine M, Van Maldergem L, et al. Prevalence of mutations in AGPAT2 among human lipodystrophies[J]. Diabetes, 2003, 52(6):1573-1578.
doi: 10.2337/diabetes.52.6.1573
pmid: 12765973
|
[4] |
郭丹丹, 刘小凤, 段元冬. 66日龄婴儿发现多发皮下结节1月余[J]. 中国当代儿科杂志, 2020, 22(8):903-908.
|
|
Guo DD, Liu XF, Duan YD. Multiple subcutaneous no-dules for 46 days in an infant aged 66 days[J]. Chin J Contemp Pediatr, 2020, 22(8):903-908.
|
[5] |
Agarwal AK, Arioglu E, de Almeida S, et al. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34[J]. Nat Genet, 2002, 31(1):21-23.
doi: 10.1038/ng880
pmid: 11967537
|
[6] |
Liu Y, Li D, Ding Y, et al. Further delineation of AGPAT2 and BSCL2 related congenital generalized lipodystrophy in young infants[J]. Eur J Med Genet, 2019, 62(9):103542.
doi: 10.1016/j.ejmg.2018.09.009
URL
|
[7] |
王怡萍, 朱彦丽, 白晋丽, 等. AGPAT2基因新变异导致先天性全身性脂肪代谢障碍Ⅰ型一例[J]. 中华医学遗传学杂志, 2020, 37(10):1158-1161.
|
|
Wang YP, Zhu YL, Bai JL, et al. Identification of a novel AGPAT2 variant in a Chinese patient with congenital generalized lipodystrophy type 1[J]. Chin J Med Genet, 2020, 37(10):1158-1161.
|
[8] |
孟源源, 吴蔚, 黄轲, 等. AGPAT2基因变异致先天性全身脂肪营养不良症1例报告并文献复习[J]. 临床儿科杂志, 2020, 38(8):599-602.
|
|
Meng YY, Wu W, Huang K, et al. Congenital generalized lipodystrophy caused by mutation of AGPAT2 gene: a case report and literature review[J]. J Chin Pediatr, 2020, 38(8):599-602.
|
[9] |
张娟, 章钟允, 李浩榕, 等. AGPAT2基因复合杂合突变导致全身性脂肪营养不良1型一例并文献复习[J]. 中华内分泌代谢杂志, 2021, 37(9):840-844.
|
|
Zhang J, Zhang ZY, Li HR, et al. Generalized lipodystrophy type 1 due to compound heterozygous mutation of AGPAT2 gene: One case report and literature teview[J]. Chin J Endocrinol Metab, 2021, 37(9):840-844.
|
[10] |
Patni N, Garg A. Congenital generalized lipodystrophies--new insights into metabolic dysfunction[J]. Nat Rev Endocrinol, 2015, 11(9):522-534.
doi: 10.1038/nrendo.2015.123
pmid: 26239609
|
[11] |
Lima JG, Nobrega LH, de Lima NN, et al. linical and laboratory data of a large series of patients with congenital generalized lipodystrophy[J]. Diabetol Metab Syndr, 2016, 8:23.
doi: 10.1186/s13098-016-0140-x
URL
|
[12] |
Garg A. Acquired and inherited lipodystrophies[J]. N Engl J Med, 2004, 350(12):1220-1234.
doi: 10.1056/NEJMra025261
URL
|
[13] |
Garg A. Lipodystrophies[J]. Am J Med, 2000, 108(2):143-152.
doi: 10.1016/s0002-9343(99)00414-3
pmid: 11126308
|
[14] |
Ren M, Shi J, Jia J, et al. Genotype-phenotype correlations of Berardinelli-Seip congenital lipodystrophy and novel candidate genes prediction[J]. OOrphanet J Rare Dis, 2020, 15(1):108.
|
[15] |
Subauste AR, Das AK, Li X, et al. Alterations in lipid signaling underlie lipodystrophy secondary to AGPAT2 mutations[J]. Diabetes, 2012, 61(11):2922-2931.
doi: 10.2337/db12-0004
pmid: 22872237
|
[16] |
Vettor R, Milan G, Rossato M, et al. Review article: adipocytokines and insulin resistance[J]. Aliment Pharmacol Ther, 2005, 22(Suppl 2):3-10.
doi: 10.1111/j.1365-2036.2005.02587.x
URL
|
[17] |
Antuna-Puente B, Boutet E, Vigouroux C, et al. Higher adiponectin levels in patients with Berardinelli-Seip congenital lipodystrophy due to seipin as compared with 1-acylglycerol-3-phosphate-o-acyltransferase-2 deficiency[J]. J Clin Endocrinol Metab, 2010, 95(3):1463-1468.
doi: 10.1210/jc.2009-1824
pmid: 20097706
|
[18] |
Musso C, Cochran E, Javor E, et al. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients[J]. Metabolism, 2005, 54(2):255-263.
doi: 10.1016/j.metabol.2004.08.021
URL
|
[19] |
Araújo-Vilar D, Santini F. Diagnosis and treatment of lipodystrophy: a step-by-step approach[J]. J Endocrinol Invest, 2019, 42(1):61-73.
doi: 10.1007/s40618-018-0887-z
pmid: 29704234
|